✦ LIBER ✦

Assessment of coenzyme q10 tolerability in huntington's disease

✍ Scribed by Dr. A. Feigin; K. Kieburtz; P. Como; C. Hickey; D. Abwender; C. Zimmerman; K. Steinberg; I. Shoulson

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 273 KB
Volume: 11
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.870110317

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We performed a 6‐month open‐label trial to evaluate the tolerability and efficacy of coenzyme Q10 (CoQ) in 10 patients with Huntington's disease (HD), Subjects were evaluated at baseline, 3 months, and 6 months using the HD Rating Scale (HDRS), the HD Functional Capacity Scale (HDFCS), and standardized neuropsychological measures. Adverse events (AEs) were assessed by telephone interview every month. CoQ doses ranged from 600 to 1,200 mg per day. All subjects completed the study, although four subjects reported mild AEs, including headache, heartburn, fatigue, and increased involuntary movements. There was no singnificant effect of the treatment on the clinical ratings. The good tolerability of CoQ suggests that it is a good candidate for evaluation in liong–term clinical trials designed to slow the progression of HD.

📜 SIMILAR VOLUMES

Safety and tolerability of high-dosage c

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects

✍ The Huntington Study Group Pre2CARE Investigators 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB 👁 1 views

Assessment of simple movements reflects

Assessment of simple movements reflects impairment in Huntington's disease

✍ Carsten Saft; Jürgen Andrich; Nina-Marie Meisel; Horst Przuntek; Thomas Müller 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

Clinical rating, caudate atrophy, disturbed movement performance, neuropsychological testing, and age-related genetic disease load (CAG index) are tools that reflect impairment after onset of Huntington's disease (HD). Objectives were to compare scored HD symptoms, results of neuropsychological test

Interrater agreement in the assessment o

Interrater agreement in the assessment of motor manifestations of Huntington's disease

✍ Penelope Hogarth; Elise Kayson; Karl Kieburtz; Karen Marder; David Oakes; Diana 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

## Abstract With prospects improving for experimental therapeutics aimed at postponing the onset of illness in preclinical carriers of the Huntington's disease (HD) gene, we assessed agreement among experienced clinicians with respect to the motor manifestations of HD, a relevant outcome measure fo

A Europe-wide assessment of current medi

A Europe-wide assessment of current medication choices in Huntington's disease

✍ Josef Priller; Daniel Ecker; Bernhard Landwehrmeyer; David Craufurd 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

s disease (HD) is a fatal neurodegenerative disorder, which usually manifests in middle age with motor, psychiatric and/or cognitive disturbances. In his recent review, Francis Walker stated that medical treatment of HD has made little progress in the past 20 years. 1 Despite a large number of repor

A randomized trial of coenzyme Q10 in mi

A randomized trial of coenzyme Q10 in mitochondrial disorders

✍ Elisa I. Glover; Joan Martin; Amy Maher; Rebecca E. Thornhill; Gerald R. Moran; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

CYTE-I-HD: Phase I dose finding and tole

CYTE-I-HD: Phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease

✍ Richard Dubinsky; Carolyn Gray 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

## Abstract Cystamine, an inhibitor of transglutaminases, slows progression of Huntington's disease in the murine model by approximately 20%. Cysteamine, the dimer of cystamine, is an orphan drug approved for the treatment of nephropathic cystinosis and has a similar benefit in the murine model but